SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-094018
Filing Date
2023-04-06
Accepted
2023-04-06 16:16:03
Documents
13
Period of Report
2023-04-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d492602d8k.htm   iXBRL 8-K 40655
2 EX-10.1 d492602dex101.htm EX-10.1 333758
  Complete submission text file 0001193125-23-094018.txt   584150

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA clvsq-20230405.xsd EX-101.SCH 2531
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE clvsq-20230405_lab.xml EX-101.LAB 17968
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clvsq-20230405_pre.xml EX-101.PRE 11250
7 EXTRACTED XBRL INSTANCE DOCUMENT d492602d8k_htm.xml XML 3507
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

IRS No.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35347 | Film No.: 23806375
SIC: 2834 Pharmaceutical Preparations